SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMULOGIC

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Hutnick who wrote (261)2/8/1999 10:31:00 AM
From: Bosco  Read Replies (1) of 305
 
Mark - if IMUL is going into full liquidation mode [I think the company is still trying to work out the details, so this is definitely a WAG <g>] here is the breakdown:

according to yahoo and last SEC 10Q, it has

1) 20.4MM shares outstanding
2) equity is ~$51MM prior to the CANTAB deal, or
2a) ~$51 - $6MM = ~$45MM plus at least 2.6MM shares of CANTAB
3) of which, ~$26MM is current asset [i.e., highly liquid]
4) possible future income is $11MM worth of CANTAB stock

so, even with a charge for termination expense of say 10% of liquid asset, there should be at least $1.20 to $2.00 cash distribution. Then, shareholders should get 1 to 2 shares of CANTAB stock for every 10 shares of IMUL, if IMUL doesn't/can't liquidate the stock holding. That is worth about $1 or 2/share [$10/(1/10)]

Therefore, therectically, it works out to $2.20 to $4.00 after all is said and done. But I think there may be a few kinks along the way.

best, Bosco
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext